



PHARMACY POLICY STATEMENT

North Carolina Marketplace



For **reauthorization**:

1. Labs must show stabilized or increased hemoglobin level compared to baseline, not to exceed 11.5 g/dL (12 g/dL for pediatrics); AND
2. Red blood cell transfusions are not required or the number of transfusions has decreased compared to baseline; AND
3. Member has adequate iron stores or is on iron therapy; AND
4. Member has not developed pure red cell aplasia (PRCA).

If all the above requirements are met, the medication will be approved for an additional 6 months.

Anemia due to Chemotherapy in Patients with Cancer

Any request for cancer must be submitted through [NantHealth/Eviti](#) portal.

CareSource considers Aranesp (darbepoetin alfa) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

| DATE | ACTION/DESCRIPTION |
|------------|--|
| 10/04/2018 | New policy for Aransep created. Hemoglobin requirement expanded. Endogenous serum erythropoietin level requirement removed. |
| 09/26/2022 | Transferred to new template. Updated all references. Separated anemia due to chemotherapy to a different section. Removed prescribers except nephrology. Clarified baseline hemoglobin levels and changed from within 14 days to within 30 days. Removed supplemental iron as a requirement (still have to meet lab values for adequate levels). Added hypertension as exclusion. Clarified hemoglobin criterion in renewal section and added upper limit. Added adequate iron to renewal criteria. Added not having PRCA to renewal criteria. |

References:

1. Aranesp [package insert]. Thousand Oaks, CA: Amgen; 2019.
2. Klinger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. *Am J Kidney Dis*